rsm1 Antibody

What is RSM01 and what is its mechanism of action?

RSM01 is a fully human IgG1 monoclonal antibody specifically targeting antigenic site Ø of the pre-fusion conformation of the RSV-F glycoprotein. The antibody functions by binding to and inhibiting the pre-fusion form of RSV glycoprotein F on the virus surface, effectively blocking a critical step in the membrane fusion process required for viral entry . The original antibody (ADI-15618) was selected from a panel of over 200 monoclonal antibodies initially identified using Adimab's B-cell technology during a high-throughput profiling study of the RSV-F antibody repertoire from healthy adults . This targeting approach allows RSM01 to exhibit highly potent neutralizing activity in the single ng/mL range (0.7–6.4) against diverse RSV-A and RSV-B isolates in vitro .

How does the structure of RSM01 contribute to its extended half-life?

RSM01 contains an engineered YTE mutation in the Fc portion of the antibody that significantly extends its half-life . This critical structural modification resulted in a measured half-life of 78 days in clinical trials, supporting the potential for single-dose protection throughout an entire RSV season . The YTE mutation specifically alters the interaction between the antibody and the neonatal Fc receptor (FcRn), reducing the rate of antibody degradation and extending circulation time. This extended half-life is particularly important for prophylactic applications in vulnerable populations where frequent dosing would present logistical challenges .

What differentiates RSM01 from other RSV monoclonal antibodies?

RSM01 distinguishes itself from other RSV antibodies through its targeting of antigenic site Ø of the pre-fusion F protein, which is considered a highly neutralization-sensitive region . The antibody underwent sequence optimization of the variable region to decrease immunogenicity (removal of T cell epitopes) and improve manufacturability . Compared to other clinically relevant monoclonal antibodies like palivizumab and nirsevimab (previously MEDI8897), RSM01 demonstrated superior neutralization potency in comparative in vitro microneutralization assays against diverse RSV isolates . Additionally, RSM01 is being specifically developed with consideration for affordability and accessibility in low- and middle-income countries (LMICs), which represents a unique focus in its development pathway .

How was epitope mapping conducted for RSM01 characterization?

Epitope mapping for RSM01 was performed using Bio-layer interferometry (BLI) with a FortèBio Octet Red96 instrument from Pall Life Sciences . The methodology involved designing peptides covering most of the surface-exposed F-trimer residues, specifically targeting antigenic sites Ø, III, IV, and V . These peptides were synthesized in both biotinylated and non-biotinylated forms to facilitate the BLI analysis. Two specific biotinylated peptides were central to this work: F-P1 peptide (Biot-GGSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQL) and F-P2 peptide (Biot-GGKNYIDKQLLPILNKQSCSISNIETVIEFQQK) . This approach allowed researchers to precisely characterize the binding specificity of RSM01 to the pre-fusion RSV F protein and confirm its targeting of the critical antigenic site Ø .

What methodologies were used to assess RSM01's neutralizing activity?

RSM01's neutralizing activity was evaluated using ELISA-based virus microneutralization assays in 96-well format . These assays compared RSM01 with clinically relevant comparator monoclonal antibodies including nirsevimab (formerly MEDI8897) and palivizumab . The assessment included testing against common laboratory strains (RSV-A2, RSV-A-Long, RSV-B1, RSV-B9320, RSV-B Wash/18537/Military, and RSV-B Wash/18537/ATCC) as well as a panel of clinical isolates collected during the 2002-2017 RSV seasons . Effective concentration leading to 50% viral neutralization (EC50) was calculated based on 11-point dilution series using non-linear curve fitting in GraphPad Prism 6.0 software . This comprehensive approach demonstrated RSM01's broad and potent neutralizing capability across diverse RSV strains, with EC50 values in the single ng/mL range (0.7–6.4) .

How was the Phase 1 clinical trial of RSM01 designed to optimize safety assessment?

The Phase 1 trial employed a rigorous randomized, double-blind, placebo-controlled design with sequential dose escalation followed by an expansion phase . The trial utilized a sentinel participant approach, where the first participant in each dose-escalation cohort received the appropriate RSM01 dose level to serve as a sentinel exposure participant . This design allowed for careful safety monitoring before exposing additional participants. The dose escalation phase enrolled participants sequentially into four cohorts: 300 mg IV (Cohort 1), followed by parallel enrollment with randomized allocation to either 300 mg IM (Cohort 2) or 1000 mg IV (Cohort 3), and finally 3000 mg IV (Cohort 4) . The dose expansion phase then enrolled participants to receive 600 mg IM (Cohort 5) . Randomization used a 6:1 ratio (RSM01:placebo) to maintain blinding while maximizing data on the investigational product . Safety data through day 15 was reviewed before each subsequent cohort enrollment, ensuring that no predefined pausing criteria had been met .

What analytical methods are used to quantify RSM01 concentrations in different sample types?

RSM01 quantification employs separate validated immunoassays for serum and dried blood extract analysis . For dried blood analysis, samples are collected using 20μL VAMS devices and extracted into 200μL buffer . Both serum and extracted blood samples undergo similar processing: they are diluted to the minimum required dilution (MRD) and captured on coated MSD plates . After incubation and washing, detection antibody conjugated to Ruthenium (MSD Sulfo Tag Gold) is added and incubated . Following a wash step, MSD Read Buffer is added, and relative light units (RLU) are captured on an MSD Sector 600 Imager . RSM01 concentration is calculated from a 5-parameter nonlinear regression curve with 1/Y² weighting of calibrators . This methodology accounts for the expected concentration differences between serum and blood samples, as antibodies generally do not partition to the cellular component, resulting in numerically lower concentrations in whole blood compared to serum .

How does RSM01's pharmacokinetic profile inform dosing strategies for clinical research?

RSM01's pharmacokinetic profile demonstrates dose-proportional increases in Tmax and AUClast after intravenous administration, with a remarkably extended half-life of 78 days . This extended half-life supports the potential for single dose per season prophylaxis against RSV infection . The pharmacokinetic data from the Phase 1 trial showed consistent behavior across various dosing levels (300mg, 1000mg, and 3000mg IV), allowing researchers to make evidence-based projections about appropriate dosing for different patient populations . For implementation in research studies, this extended half-life simplifies study protocols by potentially reducing the number of doses required throughout an RSV season, which is particularly valuable for studies in resource-limited settings . Additionally, the established correlation between RSM01 concentrations and RSV neutralizing activity in both serum and capillary blood provides researchers with flexibility in monitoring therapeutic levels using minimally invasive sampling methods .

What factors should researchers consider when incorporating RSM01 into studies targeting infant populations?

When designing studies with RSM01 in infant populations, researchers should consider several key factors informed by current development patterns. The RSM01 development program specifically targets infant populations with the eventual goal of global enrollment at clinical sites with varying resource constraints . Sample collection methodology is particularly important, as the validated use of small volumes of capillary blood (20μL via VAMS) as the primary specimen type minimizes invasiveness while still providing reliable data comparable to traditional venous sampling . This patient-centered approach reduces participant burden, a critical consideration for pediatric trials . Additionally, researchers should account for potential differences in immunogenicity between adult and infant populations; the Phase 1 trial demonstrated a low rate of anti-drug antibody (ADA) development (1/48 participants seroconverted to ADA-positive post-baseline) , but infant immune responses may differ. Finally, appropriate dose determination should consider both the pharmacokinetic profile and the goal of optimizing cost-effectiveness for implementation in low- and middle-income countries .

How can researchers optimize assay sensitivity for RSM01 in limited volume samples?

To optimize assay sensitivity with limited sample volumes, researchers can implement several strategies validated in RSM01 development. The successful implementation of volumetric absorptive microsampling (VAMS) technology demonstrates that precise 20μL blood samples can yield reliable results for multiple analytes when properly extracted and analyzed . Complete recovery of antibodies from dried blood samples was achieved using standard buffers, which maintains assay sensitivity despite reduced sample size . For immunoassay optimization, the validated approach uses a 5-parameter nonlinear regression curve with 1/Y² weighting of calibrators to calculate RSM01 concentrations from relative light units (RLU) . When analyzing neutralizing activity, researchers should consider the specific cell-based RSV neutralization assay selected for the RSM01 program, which was chosen for its low sample volume requirements, short incubation time, relatively high throughput, and use of common instrumentation . Additionally, researchers should account for the expected concentration differences between serum and blood samples, as antibodies generally do not partition to the cellular component, resulting in numerically lower concentrations in whole blood compared to serum .

How does the pre-fusion F protein targeting strategy of RSM01 compare with other epitope targeting approaches?

RSM01's targeting of antigenic site Ø on the pre-fusion F protein represents a strategically advantageous approach compared to other epitope targeting strategies. Antigenic site Ø is considered a highly neutralization-sensitive region of the RSV F protein . By binding to this critical site, RSM01 blocks the conformational changes necessary for the F protein to mediate membrane fusion, effectively preventing viral entry at an early stage of the infection process . This mechanism differs from antibodies targeting other antigenic sites (such as sites III, IV, or V) that may inhibit different aspects of the fusion process or post-attachment events . The specificity of this targeting contributes to RSM01's high potency, with neutralization activity in the single ng/mL range (0.7-6.4) against diverse RSV-A and RSV-B isolates . Researchers investigating alternative targeting strategies should consider that the pre-fusion conformation specificity is critical, as the F protein undergoes significant conformational changes during the fusion process, and antibodies targeting pre-fusion epitopes often demonstrate superior neutralizing potency compared to those targeting post-fusion conformations .

What methodological approaches can be used to evaluate RSM01's effectiveness against emerging RSV strains?

To evaluate RSM01's effectiveness against emerging RSV strains, researchers can implement a multifaceted methodological approach. The established ELISA-based virus microneutralization assay platform, which was used to test RSM01 against common laboratory strains and clinical isolates from 2002-2017, provides a foundation for this work . For emerging strains, researchers should first conduct sequencing analysis focusing on the F protein, particularly the antigenic site Ø region targeted by RSM01, to identify potentially relevant mutations . This genetic analysis can be complemented by structural modeling to predict the impact of mutations on antibody binding. Subsequently, recombinant viruses expressing variant F proteins can be generated for direct neutralization testing . The 11-point dilution series approach with non-linear curve fitting used in RSM01 development provides a sensitive method for detecting shifts in neutralization potency . For strains showing reduced susceptibility, additional binding assays such as Bio-layer interferometry (BLI) can characterize the kinetics of the antibody-antigen interaction . Finally, animal model testing using cotton rats, which demonstrated RSM01's prophylactic efficacy, can evaluate protection against variants of concern before clinical studies . This comprehensive approach will allow researchers to continually assess RSM01's effectiveness as the RSV landscape evolves.